U.S., Aug. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07142811) titled 'A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection' on Aug. 19.

Brief Summary: A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection

Study Start Date: Aug. 05

Study Type: INTERVENTIONAL

Condition: Viral Hepatitis

Intervention: DRUG: Tobevibart

Tobevibart administered by subcutaneous injection

DRUG: Elebsiran

Elebsiran administered by subcutaneous injection

DRUG: Bulevirtide

Bulevirtide administered by subcutaneous injection

Recruitment Status: RECRUITING

Sponsor: Vir Biotechnology, Inc.

Published by HT Digital Content Services with permission from Health ...